SEC Company Response from VOLITIONRX LTD (VNRX) (CIK 0000093314) (VNRX) — Jan 6, 2012
VOLITIONRX LTD (VNRX) (CIK 0000093314)
Date: Jan. 6, 2012 · CIK: 0000093314 · Accession: 0001078782-12-000024
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-30402
Letter
Securities and Exchange Commission Division of Corporation Finance Filed October 13, 2011 File No. 000-30402 Form 8-K/A Filed November 1, 2011
Re:
Dear Mr. Williamson:
VolitionRX Limited, a Delaware corporation (the “Company”), has received and reviewed your letter of November 23, 2011 (the “Comment Letter”), pertaining to the Company’s Form 8-K (the “Filing”) filed October 13, 2011 and the Company’s Form 8-K/A filed November 1, 2011 with the Securities & Exchange Commission (the “Commission”).
Per my discussion today with Brian McAllister, we hope to submit our written reply to the Commission no later than January 11, 2012, as the Company is still in the process of reviewing the financial statements and notes to the financial statements in response to the Comment Letter. Again, we apologize for the delay in responding to the Comment Letter.
In connection with the comments in your letter, we acknowledge that:
·
The Company is responsible for the adequacy and accuracy of the disclosure in the filing;
·
Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and
·
The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Again, we apologize for our delay. Please do not hesitate to contact us if you have any questions or comments in regard to this letter or the information contained herein.
Very truly yours,
VolitionRX Limited
Show Raw Text
CORRESP 1 filename1.htm SEC Correspondence January 6, 2012 Jay Williamson Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, DC 20549 Re: VolitionRX Limited Form 8-K Filed October 13, 2011 File No. 000-30402 Form 8-K/A Filed November 1, 2011 Dear Mr. Williamson: VolitionRX Limited, a Delaware corporation (the “Company”), has received and reviewed your letter of November 23, 2011 (the “Comment Letter”), pertaining to the Company’s Form 8-K (the “Filing”) filed October 13, 2011 and the Company’s Form 8-K/A filed November 1, 2011 with the Securities & Exchange Commission (the “Commission”). Per my discussion today with Brian McAllister, we hope to submit our written reply to the Commission no later than January 11, 2012, as the Company is still in the process of reviewing the financial statements and notes to the financial statements in response to the Comment Letter. Again, we apologize for the delay in responding to the Comment Letter. In connection with the comments in your letter, we acknowledge that: · The Company is responsible for the adequacy and accuracy of the disclosure in the filing; · Staff comments or changes to disclosure in response to staff comments do not foreclose the Commission from taking any action with respect to the filing; and · The Company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Again, we apologize for our delay. Please do not hesitate to contact us if you have any questions or comments in regard to this letter or the information contained herein. Very truly yours, VolitionRX Limited /s/ Cameron Reynolds Cameron Reynolds President and Chief Executive Officer 150 Orchard Road Orchard Plaza 08-02 Singapore 238841